User contributions for Sbart7
Jump to navigation
Jump to search
4 May 2019
- 01:4701:47, 4 May 2019 diff hist +287 Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes:The DEPICT-1 52-Week Study →Further Reading current
- 01:4601:46, 4 May 2019 diff hist +173 Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes:The DEPICT-1 52-Week Study →Funding
- 01:4601:46, 4 May 2019 diff hist +1,212 Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes:The DEPICT-1 52-Week Study →Criticisms
- 01:4501:45, 4 May 2019 diff hist +1,764 Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes:The DEPICT-1 52-Week Study →Outcomes
- 01:4201:42, 4 May 2019 diff hist +75 Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes:The DEPICT-1 52-Week Study →Interventions
- 01:4201:42, 4 May 2019 diff hist +86 Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes:The DEPICT-1 52-Week Study →Baseline Characteristics
- 01:4101:41, 4 May 2019 diff hist +299 Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes:The DEPICT-1 52-Week Study →Exclusion Criteria
- 01:4101:41, 4 May 2019 diff hist +125 Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes:The DEPICT-1 52-Week Study →Inclusion Criteria
- 01:4001:40, 4 May 2019 diff hist +10,532 N Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes:The DEPICT-1 52-Week Study Created page with "==Clinical Question== <!-- This should be a PICO (Population, Intervention, Comparison, Outcome) style question. As an example, the ACCORD trial's clinical question is shown b..."